Диссертация (Факторы риска формирования неблагоприятных исходов хронического гепатита С), страница 22
Описание файла
Файл "Диссертация" внутри архива находится в папке "Факторы риска формирования неблагоприятных исходов хронического гепатита С". PDF-файл из архива "Факторы риска формирования неблагоприятных исходов хронического гепатита С", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата медицинских наук.
Просмотр PDF-файла онлайн
Текст 22 страницы из PDF
2269-2274.176. Ripoll C., Groszmann R., Garcia-Tsao G. et al. Hepatic venous pressuregradient predicts development of hepatocellular carcinoma independently ofseverity of cirrhosis // J. Hepatol. – 2009. – Vol. 50. – № 5. – P. 923-928.177. Ruhl C., Menke A., Cowie C. et al.
Relationship of hepatitis C virus infectionwith diabetes in the U.S. population // Hepatology – 2014. – Vol. 60. – № 4. – P.1139-1149.178. Sangiovanni A., Prati G., Fasani P. et al. The natural history of compensated135cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients //Hepatology – 2006. – Vol.
43. – № 6. – P. 1303-1310.179. Sanyal A., Banas C., Sargeant C. et al. Similarities and differences inoutcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C //Hepatology – 2006. – Vol. 43. – № 4. – P. 682–689.180. Scherzer T.-M., Reddy K., Wrba F. et al. Hepatocellular carcinoma in longterm sustained virological responders following antiviral combination therapy forchronic hepatitis C // J. Viral Hepat. – 2008.
– Vol. 15. – № 9. – P. 659-665.181. Serfaty L., Aumaître H., Chazouillères O. et al. Determinants of outcome ofcompensated hepatitis C virus-related cirrhosis // Hepatology – 1998. – Vol. 27. –№ 5. – P. 1435-1440.182. Shi J., Zhu L., Liu S. et al.
A meta-analysis of case-control studies on thecombined effect of hepatitis B and C virus infections in causing hepatocellularcarcinoma in China // Br. J. Cancer – 2005. – Vol. 92. – № 3. – P. 607-612.183. Shiratori Y., Ito Y., Yokosuka O. et al. Antiviral therapy for cirrhotic hepatitisC: association with reduced hepatocellular carcinoma development and improvedsurvival // Ann. Intern. Med.
– 2005. – Vol. 142. – № 2. – P. 105-114.184. Simmons B., Saleem J., Heath K. et al. Long-Term Treatment Outcomes ofPatients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysisof the Survival Benefit of Achieving a Sustained Virological Response // Clin.Infect. Dis. – 2015. – Vol. 61. – № 5. – P. 730-740.185. Singal A., Manjunath H., Yopp A. et al. The effect of PNPLA3 on fibrosisprogression and development of hepatocellular carcinoma: a meta-analysis // Am.J. Gastroenterol. – 2014. – Vol. 109.
– № 3. – P. 325-334.186. Singal A., Anand B. Mechanisms of synergy between alcohol and hepatitis Cvirus // J. Clin. Gastroenterol. – 2007. – Vol. 41. – № 8. – P. 761-772.187. Singal A., Singh A., Jaganmohan S. et al. Antiviral therapy reduces risk ofhepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis // Clin.Gastroenterol.
Hepatol. – 2010. – Vol. 8 – № 2. – P. 192-199.188. Sinn D., Paik S., Kang P. Disease progression and the risk factor analysis for136chronic hepatitis C // Liver Int. – 2008. – Vol. 28 – № 10. – P. 1363-1369.189. Smith-Palmer J., Cerri K., Valentine W. Achieving sustained virologicresponse in hepatitis C: a systematic review of the clinical, economic and qualityof life benefits // BMC Infect. Dis. – 2015. – Vol. 15.
– № 1. – P. 19.190. Stepanova M., Rafiq N., Younossi Z. Components of metabolic syndrome areindependent predictors of mortality in patients with chronic liver disease: apopulation-based study// Gut – 2010. – Vol. 59. – № 10. – P. 1410-1415.191. Sterling R., Stravitz R., Luketic V. et al. A comparison of the spectrum ofchronic hepatitis C virus between Caucasians and African Americans // Clin.Gastroenterol. Hepatol. – 2004.
– Vol. 2. – № 6. – P. 469-473.192. Tavakolpour S., Sali S. Tumor Necrosis Factor-α-308 G/A Polymorphismsand Risk of Hepatocellular Carcinoma: A Meta-Analysis // Hepat. Mon. – 2016. –Vol. inpress – № inpress – P.e33537.193. Terrier B., Karras A., Cluzel P. et al. Presentation and prognosis of cardiacinvolvement in hepatitis C virus-related vasculitis // Am. J. Cardiol. – 2013. – Vol.111. – № 2. – P. 265-272.194.
Thein H.-H., Yi Q., Dore G. et al. Estimation of stage-specific fibrosisprogression rates in chronic hepatitis C virus infection: a meta-analysis and metaregression // Hepatology – 2008. – Vol. 48. – № 2. – P. 418-431.195. Thein H.-H., Yi Q., Dore G. et al. Natural history of hepatitis C virusinfection in HIV-infected individuals and the impact of HIV in the era of highlyactive antiretroviral therapy: a meta-analysis // AIDS – 2008. – Vol.
22. – № 15. –P. 1979-1991.196. Thévenot T., Regimbeau C., Ratziu V. et al. Meta-analysis of interferonrandomized trials in the treatment of viral hepatitis C in naive patients: 1999update // J. Viral Hepat. – 2001. – Vol. 8. – № 1. – P. 48-62.197. Thomas D., Astemborski J., Rai R. et al. The natural history of hepatitis Cvirus infection: host, viral, and environmental factors // JAMA – 2000.
– Vol. 284– № 4. – P. 450-456.198. Tong M., el-Farra N., Reikes A. et al. Clinical outcomes after transfusion137associated hepatitis C // N. Engl. J. Med. – 1995. – Vol. 332. – № 22. – P. 14631466.199. Toshikuni N., Izumi A., Nishino K. et al. Comparison of outcomes betweenpatients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis //J. Gastroenterol.
Hepatol. – 2009. – Vol. 24. – № 7. – P. 1276-1283.200. Trépo E., Nahon P., Bontempi G. et al. Association between the PNPLA3(rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a metaanalysis of individual participant data // Hepatology – 2014. – Vol. 59. – № 6. – P.2170-2177.201. Trinchet J.-C., Bourcier V., Chaffaut C.
et al. Complications and competingrisks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospectivecohort) // Hepatology – 2015. – Vol. 62. – № 3. – P. 737-750.202. Veldt B., Chen W., Heathcote E. et al. Increased risk of hepatocellularcarcinoma among patients with hepatitis C cirrhosis and diabetes mellitus //Hepatology – 2008.
– Vol. 47. – № 6. – P. 1856-1862.203. Veldt B., Heathcote E., Wedemeyer H. et al. Sustained virologic response andclinical outcomes in patients with chronic hepatitis C and advanced fibrosis // Ann.Intern. Med. – 2007. – Vol. 147. – № 10. – P. 677-684.204. Velosa J., Serejo F., Marinho R. Eradication of hepatitis C virus reduces therisk of hepatocellular carcinoma in patients with compensated cirrhosis // Dig. Dis.Sci. – 2011. – Vol. 56 – № 6. – P. 1853-1861.205. Wang C., Wang X., Gong G. et al. Increased risk of hepatocellular carcinomain patients with diabetes mellitus: a systematic review and meta-analysis of cohortstudies // Int.
J. cancer – 2012. – Vol. 130. – № 7. – P. 1639-1648.206. Wang Y., Zhai W., Wang H. et al. An updated meta-analysis on theassociation of X-Ray repair cross complementing group 1 codon 399polymorphism with hepatocellular carcinoma risk // Asian Pacific J. Cancer Prev.– 2014. – Vol. 15. – № 11. – P. 4443-4448.207. Watanabe H., Saito T., Shinzawa H.
et al. Spontaneous elimination of serumhepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort138study // J. Med. Virol. – 2003. – Vol. 71 – № 1. – P. 56-61.208. Westbrook R., Dusheiko G. Natural history of hepatitis C // J. Hepatol. –2014. – Vol. 61 – № 1. – P. S58-S68.209. Westin J., Lagging L., Spak F. et al. Moderate alcohol intake increasesfibrosis progression in untreated patients with hepatitis C virus infection // J. ViralHepat. – 2002. – Vol. 9.
– № 3. – P. 235-241.210. White D., Tavakoli-Tabasi S., Kuzniarek J. et al. Higher serum testosterone isassociated with increased risk of advanced hepatitis C-related liver disease inmales // Hepatology – 2012. – Vol. 55. – № 3. – P. 759-768.211. Wiese M., Berr F., Lafrenz M. et al. Low frequency of cirrhosis in a hepatitisC(genotype 1b) single-source outbreak in germany: A 20-year multicenter study //Hepatology – 2000.
– Vol. 32. – № 1. – P. 91-96.212. World Health Organization. Guidelines for the screening, care, and treatmentof persons with chronic hepatitis C infection: Updated version // Geneva: WorldHealth Organization – 2016. – April.213. World Health Organization. GLOBAL HEPATITIS REPORT // 2017. – P.68.214. Wu C.-H., Tian G.-S., Wang Q.-H. et al. [Clinical features and prognosis ofdecompensated hepatitis C virus related cirrhosis] // Zhonghua Yi Xue Za Zhi –2008. – Vol. 88.
– № 8. – P. 516-509.215. Yang Y., Luo C., Feng R. et al. The TNF-α, IL-1B and IL-10 polymorphismsand risk for hepatocellular carcinoma: a meta-analysis // J. Cancer Res. Clin.Oncol. – 2011. – Vol. 137. – № 6. – P. 947-52.216. Yang Z., Wu Q., Shi Y. et al. Epidermal growth factor 61A>Gpolymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis.// Genet. Test. Mol.
Biomarkers – 2012. – Vol. 16. – № 9. – P. 1086-91.217. Yatsuji S., Hashimoto E., Tobari M. et al. Clinical features and outcomes ofcirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused bychronic hepatitis C // J. Gastroenterol. Hepatol. – 2009. – Vol. 24. – № 2. – P. 248254.139218. Younossi Z., Kanwal F., Saab S. et al. The impact of hepatitis C burden: anevidence-based approach // Aliment.
Pharmacol. Ther. – 2014. – Vol. 39. – № 5. –P. 518-31.219. Zein N., Abdulkarim A., Wiesner R. et al. Prevalence of diabetes mellitus inpatients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestaticdisease // J. Hepatol. – 2000. – Vol. 32. – № 2. – P. 209-217.140.
